New pill shows promise for rare blood cancers in early trial
NCT ID NCT04339400
First seen Jun 06, 2026 · Last updated Jun 06, 2026
Summary
This early-phase study tested a new pill called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and check for side effects. Participants had to be 18 or older and have a specific type of blood cancer. The study is complete, but results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hematology Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
-
West China Hospital ,Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.